Akari Therapeutics ( (AKTX) ) has provided an announcement.
Akari, a biotech company, has entered into a merger with Peak Bio, aiming to create a powerhouse in advanced therapies for autoimmune and inflammatory diseases. The merger is contingent on various conditions, including shareholder approvals and regulatory green lights. Akari’s lead asset, nomacopan, is showing promise in treating a range of conditions due to its dual-action on inflammation pathways. The company is also progressing with PAS-nomacopan for treating geographic atrophy, eyeing a 2025 IND filing with the FDA. Meanwhile, Akari has suspended its HSCT-TMA program post-merger review, focusing on Peak Bio’s ADC platform and Akari’s ophthalmology program, which could offer longer dosing intervals and reduce treatment burdens for patients.
For a thorough assessment of AKTX stock, go to TipRanks’ Stock Analysis page.
